Details
Stereochemistry | RACEMIC |
Molecular Formula | C13H20N2O.ClH |
Molecular Weight | 256.772 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCCNC(C)C(=O)NC1=C(C)C=CC=C1
InChI
InChIKey=BJPJNTKRKALCPP-UHFFFAOYSA-N
InChI=1S/C13H20N2O.ClH/c1-4-9-14-11(3)13(16)15-12-8-6-5-7-10(12)2;/h5-8,11,14H,4,9H2,1-3H3,(H,15,16);1H
DescriptionSources: http://www.drugbank.ca/drugs/DB00750
Sources: http://www.drugbank.ca/drugs/DB00750
Prilocaine is a local anesthetic that is similar pharmacologically to lidocaine. Prilocaine binds to the intracellular surface of sodium channels which blocks the subsequent influx of sodium into the cell. Action potential propagation and never function is, therefore, prevented. This block is reversible and when the drug diffuses away from the cell, sodium channel function is restored and nerve propagation returns. Prilocaine acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. Currently, Prilocaine is used most often for infiltration anesthesia in dentistry.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:1903409 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11421833 |
|||
Target ID: CHEMBL1980 Sources: http://www.drugbank.ca/drugs/DB00750 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | ORAQIX Approved UseOraqix is an amide local anesthetic indicated for adults who require localized anesthesia in periodontal pockets during scaling and/or root planing. Launch Date2003 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
106 ng/mL |
42.5 mg 5 times / 3 hours multiple, buccal dose: 42.5 mg route of administration: Buccal experiment type: MULTIPLE co-administered: LIDOCAINE |
PRILOCAINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.07 μg/mL |
1.5 g single, topical dose: 1.5 g route of administration: Topical experiment type: SINGLE co-administered: LIDOCAINE |
PRILOCAINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
26000 ng × min/mL |
42.5 mg 5 times / 3 hours multiple, buccal dose: 42.5 mg route of administration: Buccal experiment type: MULTIPLE co-administered: LIDOCAINE |
PRILOCAINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.8 h |
42.5 mg 5 times / 3 hours multiple, buccal dose: 42.5 mg route of administration: Buccal experiment type: MULTIPLE co-administered: LIDOCAINE |
PRILOCAINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
70 min |
single, intravenous |
PRILOCAINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
45% |
1.5 g single, topical dose: 1.5 g route of administration: Topical experiment type: SINGLE co-administered: LIDOCAINE |
PRILOCAINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
6 mg/kg single, transdermal Dose: 6 mg/kg Route: transdermal Route: single Dose: 6 mg/kg Sources: |
unhealthy, 6 years n = 1 Health Status: unhealthy Age Group: 6 years Sex: M Population Size: 1 Sources: |
Other AEs: Methemoglobinemia... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Methemoglobinemia | 6 mg/kg single, transdermal Dose: 6 mg/kg Route: transdermal Route: single Dose: 6 mg/kg Sources: |
unhealthy, 6 years n = 1 Health Status: unhealthy Age Group: 6 years Sex: M Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
[Experiences with liposuction of established surgeons]. | 2001 |
|
From cocaine to ropivacaine: the history of local anesthetic drugs. | 2001 Aug |
|
Topical anesthetics in children: agents and techniques that equally comfort patients, parents, and clinicians. | 2001 Aug |
|
[Neurotoxicity of intrathecal lidocaine]. | 2001 Aug-Sep |
|
Topical anesthetics update: EMLA and beyond. | 2001 Dec |
|
The tumescent facial block: tumescent local anesthesia and nerve block anesthesia for full-face laser resurfacing. | 2001 Dec |
|
[Some aspects of epidural anesthesia in patients with chronic renal insufficiency]. | 2001 Jul-Aug |
|
1% lidocaine injection, EMLA cream, or "numby stuff" for topical analgesia associated with peripheral intravenous cannulation. | 2001 Jun |
|
[Can treatment of flat angiomas be proposed in the first months of life?]. | 2001 Nov |
|
Efficacy of subcutaneous and topical local anaesthesia for pain relief after resection of malignant breast tumours. | 2001 Nov |
|
A randomized double-blind, placebo-controlled trial of the EMLA patch for the reduction of pain associated with intramuscular injection in four to six-year-old children. | 2001 Nov |
|
Blood flow changes in human dental pulps when capsaicin is applied to the adjacent gingival mucosa. | 2001 Nov |
|
Pain experience during transvaginal aspiration of immature oocytes. | 2001 Nov |
|
Reflection spectroscopy of analgesized skin. | 2001 Nov |
|
Quality of anaesthesia for insertion of tension-free vaginal tape using local analgesia and sedation. | 2001 Nov |
|
Subcutaneous infusion anesthesia for dermatologic surgery in children: are we ready? | 2001 Nov-Dec |
|
Dermatosurgery using subcutaneous infusion anesthesia with prilocaine and ropivacaine in children. | 2001 Nov-Dec |
|
Local anesthesia prior to the insertion of peripherally inserted central catheters. | 2001 Nov-Dec |
|
Plasma concentrations of lignocaine and prilocaine after a 24-h application of analgesic cream (EMLA) to leg ulcers. | 2001 Oct |
|
Pain on injection of prilocaine plain vs. lidocaine with epinephrine. A prospective double-blind study. | 2001 Oct |
|
[New uses of EMLA: anesthesia for relief of pain caused by hemorrhoid thrombosis]. | 2001 Oct |
|
[Ovarian puncture in fertilization in vitro: what analgesia?]. | 2001 Sep |
|
The effect of lidocaine/prilocaine cream on an experimental wound healing model. | 2001 Sep |
|
Use of EMLA: is it an injection free alternative? | 2001 Spring |
|
Noninvasive drug delivery. | 2001 Winter |
|
[Management of leg ulcers in the elderly]. | 2002 Apr |
|
Intravenous regional guanethidine blockade in the treatment of post-traumatic complex regional pain syndrome type 1 (algodystrophy) of the hand. | 2002 Apr |
|
Immunoassay screening of lysergic acid diethylamide (LSD) and its confirmation by HPLC and fluorescence detection following LSD ImmunElute extraction. | 2002 Apr |
|
Lidocaine-prilocaine cream versus tetracaine gel for procedural pain in children. | 2002 Apr |
|
EMLA cream prior to digital nerve block for ingrown nail surgery does not reduce pain at injection of anesthetic solution. | 2002 Feb |
|
A comparison of prilocaine and lidocaine for intravenous regional anaesthesia for forearm fracture reduction in children. | 2002 Feb |
|
[Tumescent technique for local anesthesia]. | 2002 Feb |
|
Vascular and neural mechanisms of ACh-mediated vasodilation in the forearm cutaneous microcirculation. | 2002 Feb |
|
Effects of dental local anaesthetics in cardiac transplant recipients. | 2002 Feb 9 |
|
Local anesthesia with EMLA cream for maxillary sinus puncture. | 2002 Jan |
|
Evidence that the human cutaneous venoarteriolar response is not mediated by adrenergic mechanisms. | 2002 Jan 15 |
|
Use of negatively charged cyclodextrins for the simultaneous enantioseparation of selected anesthetic drugs by capillary electrophoresis-mass spectrometry. | 2002 Jan 15 |
|
Characteristics of drug substances in oily solutions. Drug release rate, partitioning and solubility. | 2002 Jan 31 |
|
In vitro effects of some anesthetic drugs on enzymatic activity of human red blood cell glucose 6-phosphate dehydrogenase. | 2002 Jan-Feb |
|
Reader questions pain and peritumoral injection. | 2002 Jan-Feb |
|
Use of EMLA cream with vasectomy. | 2002 Jul |
|
The use of glyceryl trinitrate ointment with EMLA cream for i.v. cannulation in children undergoing routine surgery. | 2002 Jun |
|
A clinical study to evaluate the efficacy of ELA-Max (4% liposomal lidocaine) as compared with eutectic mixture of local anesthetics cream for pain reduction of venipuncture in children. | 2002 Jun |
|
Lidocaine iontophoresis versus eutectic mixture of local anesthetics (EMLA) for IV placement in children. | 2002 Jun |
|
EMLA cream-induced irritant contact dermatitis. | 2002 Mar |
|
Topical anesthesia for minor gynecological procedures: a review. | 2002 Mar |
|
Reducing venipuncture and intravenous insertion pain with eutectic mixture of local anesthetic: a meta-analysis. | 2002 Mar-Apr |
|
Intravenous regional blocks with guanethidine and prilocaine combined with physiotherapy: two children with complex regional pain syndrome, type 1. | 2002 May |
|
The effects of age on neural blockade and hemodynamic changes after epidural anesthesia with ropivacaine. | 2002 May |
|
Amethocaine-lidocaine cream, a new topical formulation for preventing venopuncture-induced pain in children. | 2002 May-Jun |
Sample Use Guides
Use the included blunt tipped applicator to apply gel to gingival margins and periodontal pockets
Route of Administration:
Dental
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11421833
Prilocaine inhibited FMLP-induced CL in human leucocytes (94+/-1%, at 1 mM). In cell-free experiments, prilocaine (22+/-6%, at 1 mM) caused concentration-dependent inhibition in xanthine-xanthine oxidase-induced CL.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C245
Created by
admin on Fri Dec 15 15:35:12 GMT 2023 , Edited by admin on Fri Dec 15 15:35:12 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID2031956
Created by
admin on Fri Dec 15 15:35:12 GMT 2023 , Edited by admin on Fri Dec 15 15:35:12 GMT 2023
|
PRIMARY | |||
|
MJW015BAPH
Created by
admin on Fri Dec 15 15:35:12 GMT 2023 , Edited by admin on Fri Dec 15 15:35:12 GMT 2023
|
PRIMARY | |||
|
CHEMBL1194
Created by
admin on Fri Dec 15 15:35:12 GMT 2023 , Edited by admin on Fri Dec 15 15:35:12 GMT 2023
|
PRIMARY | |||
|
DBSALT000962
Created by
admin on Fri Dec 15 15:35:12 GMT 2023 , Edited by admin on Fri Dec 15 15:35:12 GMT 2023
|
PRIMARY | |||
|
92163
Created by
admin on Fri Dec 15 15:35:12 GMT 2023 , Edited by admin on Fri Dec 15 15:35:12 GMT 2023
|
PRIMARY | |||
|
MJW015BAPH
Created by
admin on Fri Dec 15 15:35:12 GMT 2023 , Edited by admin on Fri Dec 15 15:35:12 GMT 2023
|
PRIMARY | |||
|
32053
Created by
admin on Fri Dec 15 15:35:12 GMT 2023 , Edited by admin on Fri Dec 15 15:35:12 GMT 2023
|
PRIMARY | |||
|
217-244-0
Created by
admin on Fri Dec 15 15:35:12 GMT 2023 , Edited by admin on Fri Dec 15 15:35:12 GMT 2023
|
PRIMARY | |||
|
m9132
Created by
admin on Fri Dec 15 15:35:12 GMT 2023 , Edited by admin on Fri Dec 15 15:35:12 GMT 2023
|
PRIMARY | Merck Index | ||
|
1786-81-8
Created by
admin on Fri Dec 15 15:35:12 GMT 2023 , Edited by admin on Fri Dec 15 15:35:12 GMT 2023
|
PRIMARY | |||
|
1561008
Created by
admin on Fri Dec 15 15:35:12 GMT 2023 , Edited by admin on Fri Dec 15 15:35:12 GMT 2023
|
PRIMARY | |||
|
SUB04038MIG
Created by
admin on Fri Dec 15 15:35:12 GMT 2023 , Edited by admin on Fri Dec 15 15:35:12 GMT 2023
|
PRIMARY | |||
|
C48012
Created by
admin on Fri Dec 15 15:35:12 GMT 2023 , Edited by admin on Fri Dec 15 15:35:12 GMT 2023
|
PRIMARY | |||
|
100000085080
Created by
admin on Fri Dec 15 15:35:12 GMT 2023 , Edited by admin on Fri Dec 15 15:35:12 GMT 2023
|
PRIMARY | |||
|
758432
Created by
admin on Fri Dec 15 15:35:12 GMT 2023 , Edited by admin on Fri Dec 15 15:35:12 GMT 2023
|
PRIMARY | |||
|
2557
Created by
admin on Fri Dec 15 15:35:12 GMT 2023 , Edited by admin on Fri Dec 15 15:35:12 GMT 2023
|
PRIMARY | RxNorm | ||
|
88208-29-1
Created by
admin on Fri Dec 15 15:35:12 GMT 2023 , Edited by admin on Fri Dec 15 15:35:12 GMT 2023
|
SUPERSEDED |
ACTIVE MOIETY
SUBSTANCE RECORD